Page 2 - Fragment Analyzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fragment analyzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fragment Analyzer Today - Breaking & Trending Today

Nucleic acid analysis for sample quality assessment using the Agilent Fragment Analyzer Systems

In this application compendium, Agilent Technologies introduces the use of its Fragment Analyzer Systems for nucleic acid analysis and sample quality assessment. The Fragment Analyzer Systems offer a wide range of application kits, enabling easy sizing, qualification, and quantification of both DNA and RNA samples. Additionally the compendium also provides a brief overview of capillary electrophoresis technology and the product portfolio of Fragment Analyzer Systems. ....

Agilent Technologies , Application Note , Agilent Fragment Analyzer , Fragment Analyzer Systems , Fragment Analyzer ,

Quality control of NGS libraries with daisy chains

Agilent provides a recommendation for which assay to employ to reliably visualize daisy chain products in NGS libraries ....

Agilent Technologies , Application Note , Fragment Analyzer , Next Generation Sequencing , Daisy Chains , Quality Control ,

Fragment Analyzer Systems from Agilent Technologies

Read independent reviews on Fragment Analyzer Systems from Agilent Technologies on SelectScience ....

Agilent Fragment Analyzer , Fragment Analyzer , Fragment Analyzer Systems , Agilent Technologies ,

An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs | Virology Journal

Rabies is a lethal zoonotic disease that is mainly caused by the rabies virus (RABV). Although effective vaccines have long existed, current vaccines take both time and cost to produce. Messenger RNA (mRNA) technology is an emergent vaccine platform that supports rapid vaccine development on a large scale. Here, an optimized mRNA vaccine construct (LVRNA001) expressing rabies virus glycoprotein (RABV-G) was developed in vitro and then evaluated in vivo for its immunogenicity and protective capacity in mice and dogs. LVRNA001 induced neutralizing antibody production and a strong Th1 cellular immune response in mice. In both mice and dogs, LVRNA001 provided protection against challenge with 50-fold lethal dose 50 (LD50) of RABV. With regards to protective efficiency, an extended dosing interval (14 days) induced greater antibody production than 3- or 7-day intervals in mice. Finally, post-exposure immunization against RABV was performed to evaluate the survival rates of dogs rec ....

United States , San Diego , Baden Wüberg , Neo Bioscience , Institute Of Military Veterinary Medicine , Tree Star Inc , Guangdong Academy Of Agricultural Sciences , Institute Of Animal Health , Synbiotics Corp , Dnasei Novoprotein Scientific Inc , Sepax Technologies Inc , Research Ethics Committee Of The College , Academy Of Military Medical Sciences Changchun , G Jiangsu Synthgene Biotechnology Co , Repligen Corporation , World Organization For Animal Health , Guangdong Academy Of Agricultural Sciences Guangzhou , Boehringer Ingelheim Vetmedica Inc , Novoprotein Scientific Inc , Chinese National Institutes For Food , Academy Of Military Medical Sciences , Hytest Ltd , Animal Health , Guangdong Academy , Agricultural Sciences , Military Veterinary Medicine ,